Trial ID 22101 | Maryland Oncology Hematology Trial ID 22101 – Maryland Oncology Hematology

Trial ID 22101

Trial Information - Phase III

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Protocol ID: J2J-MC-JZLH

Sponsor: Eli Lilly And Company

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Werner MD, Jeanine

Status

PENDING OPEN

Sponsor

Eli Lilly And Company

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology